Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from gamma-interferon by a human T-cell leukemia virus-positive cell line.

Important note: Information in this article was accurate in 1984. The state of the art may have changed since the publication date.

Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from gamma-interferon by a human T-cell leukemia virus-positive cell line.

Cancer Res. 1984 Oct;44(10):4470-5. Unique Identifier : AIDSLINE MED/84282370
Kleinerman ES; Zicht R; Sarin PS; Gallo RC; Fidler IJ

Abstract: Culture supernatant fluids from the human T-cell leukemia virus-positive cell line C10/MJ-2 were found to contain a soluble factor with macrophage-activating factor (MAF) activity. The MAF activity of this culture supernatant fluid was stable at 100 degrees for 2 min and was unaffected by treatment with human anti-gamma-interferon (IFN-gamma) monoclonal antibody. Both treatments neutralized greater than 97% IFN-gamma activity from the supernatant fluid as measured by virus neutralization. Furthermore, this MAF activity was not due to contamination with endotoxins since the Limulus amebocyte lysate assay was negative (less than 0.125 ng/ml) and preincubation of the C10/MJ-2 supernatant fluid with polymyxin B did not diminish its activating potential. By contrast, human IFN-gamma rendered human monocytes tumoricidal only when combined with Salmonella typhosa lipopolysaccharide (LPS) at a minimum dose of 0.2 ng/ml. The concentrations of both LPS and IFN-gamma were crucial to achieve activation since IFN-gamma at doses less than 10 units/ml did not activate human monocytes even when combined with maximal doses of LPS (0.5 ng/ml). Finally, when human IFN-gamma admixed with LPS was preincubated with polymyxin B, its activating potential was completely abrogated. Collectively, these data suggest that the human T-cell line C10/MJ-2 constitutively produces a diffusable product distinct from IFN-gamma which activates human monocytes to lyse tumor cells. Thus, this cell line could provide a good source of a unique human MAF for future purification procedures.

Keywords: Cell Line Cells, Cultured Cytotoxicity, Immunologic Endotoxins/TOXICITY Human HTLV-BLV Viruses/*IMMUNOLOGY Interferon Type II/TOXICITY Lymphokines/*BIOSYNTHESIS/PHARMACOLOGY *Macrophage Activation Monocytes/DRUG EFFECTS/IMMUNOLOGY Polymyxin B/PHARMACOLOGY Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE

841230
M84C0043

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1984. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1984. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .